Skip to main content

Table 4 Association of G1m status with change in DAS28 at 6 months of treatment with anti-TNF

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

     

Unadjusted

Adjusted b

First replication

G1m genotype a

number

Baseline DAS28

ΔDAS28

Beta

P-value

Beta

P-value

All patients

G1m1,17+

228

6.4 ± 1.1

2.5 ± 1.3

0.03

0.52

0.07

0.13

G1m1,17-

176

6.6 ± 1.1

2.4 ± 1.3

    

INX

G1m1,17+

116

6.7 ± 0.9

2.5 ± 1.2

0.14

0.04

0.15

0.02

G1m1,17-

83

6.8 ± 1.1

2.2 ± 1.3

    

ADM

G1m1,17+

112

6.1 ± 1.1

2.4 ± 1.3

−0.07

0.32

−0.01

0.83

G1m1,17-

93

6.4 ± 1.0

2.8 ± 1.3

    

Second replication

        

INX

G1m1,17+

203

6.2 ± 1.1

2.2 ± 1.5

0.11

0.03

0.08

0.08

G1m1,17-

159

6.1 ± 1.3

1.9 ± 1.5

    
  1. aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us